- Both nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) target the same viral enzyme. Which statement accurately describes a fundamental difference in their mechanism of action?
Answer: NRTIs act as chain terminators after being incorporated into the growing viral DNA strand, while NNRTIs are not incorporated.
The correct answer is A. The key mechanistic difference is that NRTIs are nucleoside/tide analogs that, after phosphorylation, are incorporated by reverse transcriptase into the proviral DNA. Because they lack a 3'-hydroxyl group, they terminate DNA chain elongation. NNRTIs, in contrast, are not incorporated into the DNA; they bind to an allosteric (non-catalytic) site on the enzyme, inducing a conformational change that inactivates it. B and C have the mechanisms reversed. D is incorrect; NNRTIs are generally not active against HIV-2, whereas most NRTIs are.
- A patient on a long-term ART regimen presents with bilateral dorsocervical fat pad enlargement ('buffalo hump'), central fat accumulation, hyperlipidemia, and new-onset insulin resistance. Which antiretroviral class, particularly its older agents, is most strongly associated with this constellation of metabolic complications?
Answer: Protease inhibitors (PIs)
The correct answer is B. The clinical picture described is characteristic of HIV-associated lipodystrophy syndrome, which includes both lipohypertrophy (fat accumulation) and metabolic disturbances like dyslipidemia and insulin resistance. This syndrome is most classically associated with older protease inhibitors (e.g., indinavir, nelfinavir). While INSTIs (A) can be associated with weight gain, it is typically not in the classic lipodystrophic pattern. Older NRTIs (C) are associated with the opposite effect, lipoatrophy (fat loss), particularly in the face and limbs. CCR5 antagonists (D) are not strongly linked to this specific metabolic syndrome.
- A patient newly diagnosed with HIV is initiated on monotherapy with lamivudine. Within a few months, virologic failure is observed, characterized by a rapid rebound in plasma HIV RNA. What is the most likely molecular explanation for this treatment failure?
Answer: The M184V mutation in the reverse transcriptase gene developed, conferring high-level resistance to lamivudine.
The correct answer is A. HIV monotherapy fails due to the rapid selection of drug-resistant viral variants. For lamivudine (and emtricitabine), the M184V mutation in reverse transcriptase is a single point mutation that can be selected quickly and confers high-level resistance, making it a classic example of why combination therapy is essential. B is incorrect because while P-glycoprotein efflux is a mechanism of drug resistance in some contexts (e.g., oncology), it is not the primary mechanism for HIV resistance to NRTIs. C is incorrect as NRTIs like lamivudine are not major substrates for CYP450 enzymes. D is incorrect because a mutation in the protease enzyme would confer resistance to protease inhibitors, not to an NRTI like lamivudine, which targets reverse transcriptase.
- A patient with multi-drug resistant HIV is being considered for treatment with the CCR5 antagonist maraviroc. Which of the following evaluations is an essential prerequisite before this specific agent can be initiated?
Answer: A viral tropism assay to determine if the virus utilizes the CCR5 co-receptor for cell entry.
The correct answer is B. Maraviroc is a CCR5 antagonist, meaning it blocks the CCR5 co-receptor on the surface of CD4+ cells, which some strains of HIV use to enter the cell. However, other HIV strains use a different co-receptor, CXCR4 (X4-tropic), or both (dual/mixed-tropic). Maraviroc is only effective against CCR5-tropic virus. Therefore, a tropism test is mandatory before starting therapy to ensure the patient's virus is susceptible. A is the prerequisite test for abacavir. C would be relevant for starting an INSTI. D is important for dose-adjusting many drugs, but it is not the specific, essential prerequisite for maraviroc's mechanism of action.
- Current guidelines for initial antiretroviral therapy typically recommend a regimen consisting of two NRTIs plus a third active drug (e.g., an INSTI). What is the primary pharmacological rationale for using this two-NRTI 'backbone' structure?
Answer: To provide a robust foundation for viral suppression and a higher barrier to resistance through complementary activity.
The correct answer is C. The two-NRTI backbone is the cornerstone of combination ART because the two drugs provide potent, synergistic suppression of reverse transcriptase. Using two NRTIs together contributes significantly to the regimen's overall potency and durability. It also helps create a higher genetic barrier to resistance compared to using a single NRTI. A is incorrect; NRTIs only target reverse transcriptase. B is not the primary reason; while some NRTIs have long half-lives, this is not a universal property or the main rationale. D is incorrect; NRTIs are not effective against the latent reservoir.
- An HIV specialist describes a new antiretroviral agent as having a 'high genetic barrier to resistance.' This pharmacological characteristic implies which of the following?
Answer: The development of clinically significant resistance requires the virus to accumulate multiple mutations.
The correct answer is C. The 'genetic barrier to resistance' refers to the number of viral mutations required to overcome the drug's effect. A high genetic barrier means that multiple mutations must accumulate before clinically significant resistance emerges. This makes the drug more 'forgiving' of minor lapses in adherence. Boosted protease inhibitors and second-generation INSTIs like dolutegravir are examples of drugs with high barriers. B describes a low genetic barrier, characteristic of NNRTIs and lamivudine/emtricitabine. A and D describe pharmacokinetic properties and spectrum of activity, respectively, not the genetic barrier.
- A patient on a first-line regimen containing efavirenz experiences a short period of non-adherence, missing several doses over two weeks. Upon re-testing, a high viral load is detected along with a new K103N mutation in the reverse transcriptase gene. This clinical scenario most clearly illustrates which key concept regarding the NNRTI class?
Answer: The low genetic barrier to resistance, where a single mutation can cause high-level class resistance.
The correct answer is D. The first-generation NNRTIs (e.g., efavirenz, nevirapine) are known for having a low genetic barrier to resistance. This means that a single point mutation, such as the classic K103N, can confer high-level resistance to the entire class. The scenario of rapid failure after a brief period of non-adherence is a classic illustration of this vulnerability. A describes a known side effect of efavirenz but is not what the resistance data illustrates. B is the opposite of what is observed. C is incorrect, as NNRTIs are not pharmacokinetically boosted.
- A patient's regimen is being switched from a boosted protease inhibitor (PI)-based regimen to an integrase inhibitor (INSTI)-based regimen. A potential advantage the patient is likely to experience with the new INSTI regimen is a significantly lower risk of developing:
Answer: long-term metabolic complications such as hyperlipidemia and insulin resistance.
The correct answer is C. Protease inhibitors as a class, particularly when boosted with ritonavir, are strongly associated with metabolic side effects, including hyperlipidemia, insulin resistance, and lipodystrophy. While newer PIs are better tolerated, the class effect remains a concern. INSTIs generally have a much more favorable metabolic profile, making this a common reason for switching. A is characteristic of older NRTIs (e.g., stavudine). B can be a concern with some INSTIs (e.g., dolutegravir) and was a hallmark of the NNRTI efavirenz. D is specific to the NRTI abacavir.
- A clinician is choosing between an NNRTI-based regimen and an INSTI-based regimen for a treatment-naive patient with a complex medication history. Which of the following represents a key pharmacological distinction that favors the selection of a modern INSTI-based regimen in this scenario?
Answer: INSTIs generally have a more favorable profile regarding drug-drug interactions mediated by the cytochrome P450 system.
The correct answer is B. Modern integrase strand transfer inhibitors (INSTIs) like bictegravir and dolutegravir generally have fewer and less severe drug-drug interactions compared to older NNRTIs (e.g., efavirenz) and protease inhibitors, which are notorious for their complex interactions as substrates, inhibitors, or inducers of CYP450 enzymes. This makes INSTIs a preferred choice in patients on multiple medications. A is incorrect; NNRTIs (especially first-generation ones) have a low genetic barrier to resistance. C is a true statement about NNRTIs but not the primary clinical reason to prefer an INSTI, as both classes have rapid antiviral effects. D is incorrect; this describes the mechanism of entry inhibitors, not INSTIs, which block the integration of viral DNA into the host genome.
- A patient on an older ART regimen containing stavudine (d4T) develops painful peripheral neuropathy and pancreatitis. These dose-limiting toxicities are primarily attributed to the drug's off-target inhibition of which essential host cell enzyme?
Answer: Mitochondrial DNA polymerase gamma
When you encounter questions about nucleoside reverse transcriptase inhibitors (NRTIs) like stavudine causing peripheral neuropathy and pancreatitis, think about mitochondrial toxicity. These symptoms are classic signs of mitochondrial dysfunction, which helps point you toward the mechanism.
Stavudine's dose-limiting toxicities stem from its off-target inhibition of mitochondrial DNA polymerase gamma (pol γ). This enzyme is responsible for replicating mitochondrial DNA, which is essential for cellular energy production. When stavudine inhibits pol γ, it disrupts mitochondrial DNA synthesis, leading to mitochondrial dysfunction. Tissues with high energy demands—like peripheral nerves and pancreatic cells—are particularly vulnerable, explaining why patients develop painful neuropathy and pancreatitis.
Answer choice A (Cytochrome P450 3A4) is incorrect because this hepatic enzyme metabolizes drugs but doesn't cause the specific mitochondrial toxicities described. Choice B (Cellular topoisomerase I) is wrong—this nuclear enzyme relieves DNA supercoiling during replication but isn't the target causing these particular side effects. Choice C (Host cell RNA polymerase II) is also incorrect since this enzyme transcribes mRNA in the nucleus and wouldn't produce mitochondrial dysfunction symptoms.
The correct answer is D because mitochondrial DNA polymerase gamma inhibition directly explains both the mechanism and the clinical presentation.
Study tip: Remember that older NRTIs (stavudine, didanosine, zidovudine) commonly cause mitochondrial toxicity through pol γ inhibition. When you see peripheral neuropathy, pancreatitis, or lactic acidosis with these drugs, think mitochondrial DNA polymerase gamma—it's a high-yield association for pharmacology exams.
- A patient's antiretroviral regimen includes darunavir co-administered with a low dose of ritonavir. The primary pharmacological purpose of including ritonavir in this regimen is to:
Answer: inhibit intestinal and hepatic CYP3A4, thereby increasing the bioavailability and prolonging the half-life of darunavir.
The correct answer is B. Low-dose ritonavir is used as a pharmacokinetic enhancer, or 'booster.' Its primary role is to potently inhibit the cytochrome P450 3A4 (CYP3A4) enzyme in the gut and liver. This reduces the first-pass metabolism of other protease inhibitors like darunavir, leading to higher plasma concentrations ('boosting'), a longer half-life, and allowing for less frequent dosing. A is incorrect because at the low doses used for boosting, ritonavir's own antiretroviral activity is minimal. C is incorrect; the purpose is pharmacokinetic, not resistance prevention in this manner. D is incorrect because protease inhibitors are not pro-drugs and do not require intracellular phosphorylation to be active.
- A patient's HIV genotype report reveals the M184V mutation in reverse transcriptase, conferring high-level resistance to lamivudine. Paradoxically, the presence of the M184V mutation is known to increase the in-vitro susceptibility of the virus to which of the following antiretroviral agents?
Answer: Tenofovir
When you encounter HIV drug resistance questions, focus on how mutations can create unexpected drug interactions and cross-resistance patterns. The M184V mutation is particularly important because while it causes high-level resistance to certain drugs, it can paradoxically enhance sensitivity to others.
The M184V mutation in HIV reverse transcriptase creates a fascinating pharmacological phenomenon. This mutation substitutes valine for methionine at position 184, which not only confers resistance to lamivudine and emtricitabine but also reduces the enzyme's processivity and fidelity. This reduction in viral fitness creates hypersusceptibility to tenofovir (D). The M184V mutation appears to impair the virus's ability to discriminate against tenofovir, making it more likely to incorporate this nucleotide analog, thereby increasing the drug's antiviral efficacy.
Efavirenz (A) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works at a different binding site than nucleoside analogs, so M184V doesn't create hypersusceptibility to it. Atazanavir (B) is a protease inhibitor that targets a completely different enzyme, making it unaffected by reverse transcriptase mutations. Dolutegravir (C) is an integrase inhibitor that acts on yet another viral enzyme, so reverse transcriptase mutations don't influence its activity.
Remember this key principle: the M184V mutation creates a "fitness cost" that can be exploited therapeutically. When studying HIV pharmacology, pay special attention to how resistance mutations can sometimes create vulnerabilities to other drugs in the same class—this concept appears frequently on pharmacology exams and is clinically relevant for treatment planning.
- Cobicistat is a pharmacokinetic enhancer included in several single-tablet HIV regimens. Its mechanism is analogous to that of low-dose ritonavir, but it differs from ritonavir in what key pharmacological aspect?
Answer: Cobicistat lacks intrinsic antiretroviral activity against HIV.
The correct answer is C. The most significant difference between cobicistat and ritonavir as pharmacokinetic enhancers is that cobicistat is a dedicated CYP3A4 inhibitor with no antiretroviral activity of its own. Ritonavir, in contrast, is an HIV protease inhibitor that, even at low boosting doses, retains some (albeit minimal) antiretroviral effect. This distinction makes cobicistat a 'purer' boosting agent. A is incorrect; this describes ritonavir, not cobicistat. B and D are incorrect as cobicistat's primary mechanism, like ritonavir's, is potent inhibition of CYP3A4.
- The fusion inhibitor enfuvirtide must be administered via subcutaneous injection twice daily. This demanding route of administration is a direct consequence of the drug's fundamental chemical nature, which is that of a:
Answer: large synthetic peptide that would be rapidly degraded by proteases in the gastrointestinal tract.
The correct answer is B. Enfuvirtide is a 36-amino-acid synthetic peptide that mimics a segment of the HIV gp41 protein. As a peptide, if taken orally, it would be digested by proteases in the stomach and small intestine and not absorbed intact. Therefore, it must be administered parenterally, via subcutaneous injection. A describes many oral drugs, but not a peptide. C is incorrect; it is not a pro-drug requiring local activation. D describes properties of some NRTIs, but enfuvirtide is not a nucleotide analog.
- The antiretroviral activity of tenofovir disoproxil fumarate (TDF) is dependent on a series of intracellular events. Which sequence correctly represents the steps required for TDF to inhibit HIV replication?
Answer: Hydrolysis to tenofovir -> Phosphorylation to tenofovir diphosphate -> Competitive inhibition of reverse transcriptase.
The correct answer is C. TDF is a pro-drug. First, esterases in the plasma and cells hydrolyze it to its active form, tenofovir. Tenofovir is a nucleotide analog, so it is then phosphorylated twice by host cell kinases to become tenofovir diphosphate. This active metabolite competes with the natural substrate (deoxyadenosine triphosphate) for incorporation by reverse transcriptase into the growing viral DNA, causing chain termination. A is incorrect because it is incorporated into DNA, not RNA. B is incorrect because TDF is an NRTI, not a PI, and the prodrug itself is not phosphorylated. D describes the mechanism of an NNRTI.
- Ibalizumab is a monoclonal antibody used for multi-drug resistant HIV. Its mechanism of action is distinct from other entry inhibitors like maraviroc and enfuvirtide. Ibalizumab exerts its antiviral effect by:
Answer: binding to domain 2 of the CD4 receptor on the host cell, which blocks viral entry after the initial attachment has occurred.
When you encounter questions about HIV entry inhibitors, focus on understanding the sequential steps of viral entry: initial binding, conformational changes, co-receptor engagement, and membrane fusion. Each inhibitor targets a specific step in this cascade.
Ibalizumab works through a unique mechanism among entry inhibitors. It binds to domain 2 of the CD4 receptor on host T-cells, creating a physical barrier that prevents the virus from completing entry even after it has already attached to the cell. This post-attachment inhibition is what makes it distinct from other entry inhibitors and particularly valuable against multi-drug resistant HIV strains.
Let's examine why the other options are incorrect. Option B describes maraviroc's mechanism - it's a CCR5 antagonist that blocks the co-receptor, not ibalizumab's target. Option C describes enfuvirtide's mechanism, which binds to gp41 and prevents the conformational changes needed for membrane fusion. Option D is completely off-target since protease inhibitors work intracellularly after infection has occurred, and ibalizumab is an entry inhibitor, not a protease inhibitor.
The correct answer is A because ibalizumab specifically targets domain 2 of CD4, creating a unique post-attachment block that distinguishes it from pre-attachment inhibitors.
For pharmacology exams, remember that HIV drug mechanisms often follow the viral life cycle sequence. Entry inhibitors can work at different stages: pre-attachment (maraviroc), post-attachment (ibalizumab), or during fusion (enfuvirtide). Understanding where each drug acts in this sequence will help you tackle similar questions systematically.
- The primary goal of modern antiretroviral therapy (ART) is to achieve and maintain a plasma HIV RNA level below the limit of detection. According to major public health findings, what is the most significant clinical and social consequence of a patient achieving and maintaining this state?
Answer: The risk of transmitting HIV to sexual partners is reduced to effectively zero.
The correct answer is C. Large clinical trials have demonstrated that when a person with HIV achieves and maintains an undetectable viral load through ART, they do not sexually transmit the virus to others. This concept is known as 'Undetectable = Untransmittable' (U=U). It is a profound consequence of effective ART, with major implications for public health, prevention, and reducing stigma. A is incorrect; ART suppresses replication but does not eradicate the latent reservoir, which is why it is not a cure. B is incorrect; while immune function (CD4 count) improves dramatically, some immune dysregulation and inflammation may persist. D is incorrect; ART reduces the risk of non-AIDS comorbidities but does not eliminate it entirely.
- A pregnant patient with HIV is being managed to prevent perinatal transmission. Historically, zidovudine (AZT), an NRTI, was a key component of therapy. What is the specific molecular mechanism by which activated zidovudine suppresses HIV replication?
Answer: It competitively inhibits the incorporation of thymidine triphosphate during viral DNA synthesis.
When you encounter questions about nucleoside reverse transcriptase inhibitors (NRTIs) like zidovudine, focus on their mechanism as DNA chain terminators that mimic natural nucleosides.
Zidovudine works by mimicking thymidine, one of the four natural DNA building blocks. Once phosphorylated to its triphosphate form inside the cell, zidovudine triphosphate competes directly with natural thymidine triphosphate for incorporation into the growing viral DNA chain during reverse transcription. However, zidovudine lacks a 3'-hydroxyl group, so when it's incorporated, DNA synthesis terminates because no further nucleotides can be added. This competitive inhibition effectively blocks HIV replication at the reverse transcription step.
Choice A describes non-nucleoside reverse transcriptase inhibitors (NNRTIs) like efavirenz, which bind to an allosteric site and change the enzyme's shape rather than competing for the active site. Choice B incorrectly describes integrase strand transfer inhibitors like raltegravir, which target a completely different step in the HIV life cycle. Choice C describes protease inhibitors, which prevent proper viral protein processing rather than affecting DNA synthesis.
The correct answer is D because zidovudine triphosphate directly competes with thymidine triphosphate during viral DNA synthesis, leading to chain termination.
Study tip: Remember that NRTIs are "fake building blocks" - they compete with natural nucleotides (competitive inhibition) and terminate DNA chains, while NNRTIs work through allosteric inhibition. This distinction frequently appears on pharmacology exams when testing antiretroviral mechanisms.
